WASHINGTON, April 6, 2012 /PRNewswire-USNewswire/ -- In partnership with Corcept Therapeutics Inc., the National Organization for Rare Disorders (NORD) has established a Cushing's Syndrome Patient

A new investigational drug significantly reduced urinary cortisol levels and improved symptoms of Cushing's disease in the largest clinical study of this endocrine disorder ever conducted.

Cushing’s disease is a rare disorder of chronic hypercortisolism due to a corticotropin-secreting pituitary adenoma. Despite high remission, surgery has been the best option to treat it. Now doctors are shedding light on a new way to target the disease.

EAST HANOVER, N.J., March 7, 2012 /PRNewswire/ -- A study published in The New England Journal of Medicine (NEJM) found that the investigational drug Signifor® (SOM230, pasireotide),

http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm